Events
-
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
-
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
-
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
-
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
-
-
Researchers find growth mechanism present in 90 percent of cancer cells
A progression mechanism found in 90 percent of cancers has been discovered, suggesting a new…
New report confirms critical role GPs play in reducing the impact of bowel cancer
Cancer Council and the Australian Government are calling on Australian GPs to use their influence…
Programmed cell death in cancer cells: Overcoming resistance through paraptosis-inducing compounds
Apoptosis, a type of programmed cell death (PCD), is a biological process through which unwanted…
SABCS 2022: Treatment decision guided by CTC count may improve long-term outcomes for mBC
- SABCS 2022: The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
- SABCS 2022: Genetic profiling may identify patients with breast cancer who can safely omit radiation therapy after breast-conserving surgery
- SABCS 2022: Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse short-term recurrence rates
Immunotherapy before liver cancer surgery can kill tumour, and likely residual cancer cells
- ASCO GI 2022: Durvalumab significantly improves survival for patients with biliary tract cancer compared to chemotherapy alone
- ASCO GI 2022: Durvalumab plus tremelimumab significantly improves survival for patients with advanced liver cancer compared to sorafenib
- Mouse study identifies bacterial protein associated with colorectal cancers
Blood test can predict clinical response to immunotherapy in metastatic NSCLC
- First-ever pathology of the early phase of lung infection with the 2019 novel coronavirus (COVID-19)
- Protected: TECENTRIQ® (atezolizumab) first immunotherapy to be reimbursed for 1L treatment of extensive-stage small cell lung cancer
- Study shows long-term survival benefit for certain patients with advanced lung cancer
Patients now living a median 6.8 years after stage IV ALK positive lung cancer diagnosis
According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.